<DOC>
	<DOCNO>NCT00403052</DOCNO>
	<brief_summary>The main objective study establish safe , tolerable active dose 1018 ISS administer combination irinotecan cetuximab patient metastatic colorectal cancer . Other objective also include determine tumor response , time disease progression , overall survival treat patient .</brief_summary>
	<brief_title>A Study 1018 Immunostimulatory Sequence ( ISS ) Administered With Irinotecan Cetuximab Treat Patients With Previously Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This Phase I , open-label study escalate dose level 1018 ISS combination irinotecan cetuximab patient previously treat metastatic colorectal cancer . Approximately 15 patient treat . The objective study establish safe , tolerable , active dose 1018 ISS , determine tumor response , time disease progression , overall survival treat patient . The safety tolerability 1018 ISS evaluate periodic laboratory assessment , physical examination , compilation adverse event . Once study patient consent , screen , assign one dose level 1018 ISS , patient receive two 4 week cycle 1018 ISS therapy plus irinotecan every week cetuximab weekly . Irinotecan cetuximab continue thereafter disease progression , unacceptable toxicity , patient refuse treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed , write , informed consent must obtain patient legal representative studyspecific procedure perform Confirmed diagnosis adenocarcinoma colon rectum amenable curative surgery One prior systemic therapy regimens metastatic cancer must include fluoropyrimidine ( 5fluorouracil ( FU ) infusion capecitabine ) , oxaliplatin irinotecan without bevacizumab Clinically significant obstructive symptom , intestinal bleeding , chronic recent acute gastrointestinal disorder diarrhea major symptom History unstable deteriorate cardiovascular cerebrovascular disease within 3 month first dose protocol therapy Clinical evidence brain metastasis central nervous system disease Pregnant lactate woman Serious medical psychiatric illness Malignancy colorectal carcinoma within past 2 year , except curatively treat , superficial skin cancer carcinoma situ cervix Patients experimental study antitumor therapy , receive radiotherapy , prior surgery ( except venous access device placement ) within 28 day first dose protocol therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>carcinoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>colon</keyword>
	<keyword>rectal</keyword>
	<keyword>neoplasm</keyword>
	<keyword>cetuximab</keyword>
	<keyword>irinotecan</keyword>
	<keyword>1018 ISS</keyword>
	<keyword>combination therapy</keyword>
</DOC>